Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 219

1.

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.

Maziarz RT, Brazauskas R, Chen M, McLeod AA, Martino R, Wingard JR, Aljurf M, Battiwalla M, Dvorak CC, Geroge B, Guinan EC, Hale GA, Lazarus HM, Lee JW, Liesveld JL, Ramanathan M, Reddy V, Savani BN, Smith FO, Strasfeld L, Taplitz RA, Ustun C, Boeckh MJ, Gea-Banacloche J, Lindemans CA, Auletta JJ, Riches ML.

Bone Marrow Transplant. 2016 Dec 19. doi: 10.1038/bmt.2016.259. [Epub ahead of print]

PMID:
27991895
2.

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.

Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR; from the Center for International Blood and Marrow Transplantation Research..

Haematologica. 2016 Nov;101(11):1426-1433.

3.

Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.

Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P.

Bone Marrow Transplant. 2017 Jan;52(1):20-27. doi: 10.1038/bmt.2016.194.

PMID:
27618682
4.

Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.

Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer D, Horowitz MM, Anasetti C.

JAMA Oncol. 2016 Dec 1;2(12):1583-1589. doi: 10.1001/jamaoncol.2016.2520.

PMID:
27532508
5.

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.

Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1893-9. doi: 10.1016/j.bbmt.2016.07.007.

PMID:
27496215
6.

Mesenchymal stromal cells: potential roles in graft-versus-host disease prophylaxis and treatment.

Maziarz RT.

Transfusion. 2016 Apr;56(4):9S-14S. doi: 10.1111/trf.13563. Review. No abstract available.

PMID:
27079324
7.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W.

J Clin Oncol. 2016 Jun 1;34(16):1864-71. doi: 10.1200/JCO.2015.65.0515.

PMID:
27044940
8.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.

Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1056-64. doi: 10.1016/j.bbmt.2016.02.015.

PMID:
26964698
9.

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.

Munker R, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W; Center for International Blood and Marrow Transplant Research..

Biol Blood Marrow Transplant. 2016 Jun;22(6):1024-9. doi: 10.1016/j.bbmt.2016.02.013.

PMID:
26903380
10.

Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.

Riches ML, Trifilio S, Chen M, Ahn KW, Langston A, Lazarus HM, Marks DI, Martino R, Maziarz RT, Papanicolou GA, Wingard JR, Young JA, Bennett CL.

Bone Marrow Transplant. 2016 Feb;51(2):322. doi: 10.1038/bmt.2015.318. No abstract available.

PMID:
26838373
11.

Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.

Riches ML, Trifilio S, Chen M, Ahn KW, Langston A, Lazarus HM, Marks DI, Martino R, Maziarz RT, Papanicolou GA, Wingard JR, Young JA, Bennett CL.

Bone Marrow Transplant. 2016 Feb;51(2):277-82. doi: 10.1038/bmt.2015.263. Erratum in: Bone Marrow Transplant. 2016 Feb;51(2):322.

12.

Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells.

Burrows GG, Van't Hof W, Reddy AP, Wilmarth PA, David LL, Raber A, Bogaerts A, Timmerman L, Pinxteren J, Roobrouck VD, Deans RJ, Maziarz RT.

Stem Cells Transl Med. 2015 Dec;4(12):1436-49. doi: 10.5966/sctm.2014-0225.

13.

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG.

Cancer. 2015 Oct 15;121(20):3709-16. doi: 10.1002/cncr.29498.

14.

Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.

Vaughn JE, Gooley T, Maziarz RT, Pulsipher MA, Bhatia S, Maloney DG, Sandmaier BM, Flowers ME, Storb R, Sorror ML.

Br J Haematol. 2015 Nov;171(3):411-6. doi: 10.1111/bjh.13591.

15.

Chronic GvHD-associated serositis and pericarditis.

Leonard JT, Newell LF, Meyers G, Hayes-Lattin B, Gajewski J, Heitner S, Nonas S, Allen B, Stentz A, Frires R, Maziarz RT, Holtan SG.

Bone Marrow Transplant. 2015 Aug;50(8):1098-104. doi: 10.1038/bmt.2015.105.

PMID:
25961774
16.

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.

ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, Syrjala KL, Martin PJ, Maloney DG, Sandmaier BM, Storb R, Sorror ML.

Br J Haematol. 2015 Aug;170(4):574-83. doi: 10.1111/bjh.13476.

17.

Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, Maertens J, Deans RJ, Van't Hof W, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025.

18.

Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.

Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W.

Biol Blood Marrow Transplant. 2015 Mar;21(3):552-8. doi: 10.1016/j.bbmt.2014.12.010.

19.

Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.

Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT.

Biol Blood Marrow Transplant. 2015 Jan;21(1):89-96. doi: 10.1016/j.bbmt.2014.09.024.

20.

Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.

Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML.

Biol Blood Marrow Transplant. 2015 Jan;21(1):151-8. doi: 10.1016/j.bbmt.2014.10.006.

Items per page

Supplemental Content

Loading ...
Support Center